The frequency of CD56dimCD16- NK, which among NK subsets display an intermediate maturation level (in terms of proliferating and cytotoxic activity), was shown to be higher in non-relapsing than in relapsing patients, confirming previous data showing the association of this NK subset with better clinical outcome in melanoma patients treated with vaccination and high-dose IFN-α2b (50). Here, IFNA2 is linked to melanoma.